Great Lakes NeuroTechnologies adds Continuous Monitoring to its KinesiaU motor assessment system for iPhone and Apple Watch

06 January 2022: Independence, OH – Great Lakes NeuroTechnologies (GLNT) announced today that it has released a new version of its KinesiaU™ motor assessment system for patients with Parkinson’s disease to continuously monitor their motor symptoms using their iPhones and Apple Watches. First released in 2019 for Android and 2021 for Apple, the KinesiaU motor assessment system [ www.KinesiaU.com ] enables patients with Parkinson’s disease to track their tremor, slowness, and dyskinesia in response to therapy using a smartwatch and smartphone app. The updated system will record patients’ motor symptoms continuously throughout the day during activities of daily living in addition to the task-based assessments already present. Patients will be able to view their symptoms in user-friendly reports on their smartphones for both continuous recordings and task-based assessments. Clinicians can access patient reports in real-time through the KinesiaU provider portal and use the information to help make better care decisions and identify therapies and activities to improve their patients’ symptoms.

According to GLNT President and COO, Dustin Heldman, Ph.D., “We are thrilled to add continuous smartwatch monitoring to the KinesiaU system. This addition will allow patients to simply wear their watch throughout the day without having to interact with the app. The information will help doctors determine how symptoms respond to medication throughout the day and lead to faster therapy optimization without requiring an office visit.”

Based on Great Lakes NeuroTechnologies’ 15 years of development and validation of its patented and FDA-cleared Kinesia™ technology, KinesiaU is the only validated system for real-time remote patient monitoring of Parkinson’s disease. The KinesiaU motor assessment system is currently available in the US by prescription.

About Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies [ www.GLNeuroTech.com ] is committed to pioneering innovative biomed technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.

About Kinesia™ Technology

GLNT commercialized Kinesia™ technology to provide wearable, objective and automated assessment of movement disorders such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. The technology is protected by US and international patents listed at https://www.glneurotech.com/patents/.

Media Relations

Bill Bauza 216-446-2431 bbauza@glneurotech.com